Katora

Sildenafil citrate, the active ingredient in Katora, is a phosphodiesterase type 5 (PDE5) inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of erectile dysfunction and pulmonary arterial hypertension in adult patients. GNH USA supplies Katora as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sildenafil citrate acts on the phosphodiesterase type 5 pathway to improve vascular function in specific conditions.

Erectile dysfunction: enhances the ability to achieve and maintain an erection when sexually stimulated. Pulmonary arterial hypertension: lowers pulmonary arterial pressure and improves exercise capacity.

Sildenafil citrate may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache - Flushing - Dyspepsia - Nasal congestion

Serious or Rare Side Effects: - Priapism (prolonged erection) - Sudden loss of vision - Sudden loss of hearing - Myocardial infarction or stroke - Severe hypotension

Before prescribing sildenafil citrate, clinicians should consider several safety factors.

Cardiovascular assessment: evaluate recent myocardial infarction or unstable angina. Nitrate therapy: avoid concurrent use due to risk of profound hypotension. Retinal disorders: use with caution in patients with inherited retinal disease. Blood pressure monitoring: assess patients with hypotension or uncontrolled hypertension. Drug interaction review: check all concomitant medications for potential interactions. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Sildenafil citrate can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin): may cause severe hypotension. - Guanylate cyclase stimulators (e.g., riociguat): risk of additive blood pressure lowering. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase sildenafil exposure.

Moderate Interactions (Monitor Closely): - Alpha‑blockers: may cause additive hypotensive effects. - CYP3A4 inducers (e.g., rifampin): may reduce sildenafil effectiveness. - Other PDE5 inhibitors: concurrent use can increase risk of adverse events.